spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Eisai 

 HSMN NewsFeed - 6 Sep 2023
Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jul 2022
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 20 Apr 2022
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2021
Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Sep 2021
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Sep 2021
Neuroglee Therapeutics Closes Series A Round to Advance Virtual Care and Digital Therapies for Alzheimer's Disease Treatment in the Home
Devices Neurology Venture Capital
 HSMN NewsFeed - 1 Jul 2021
Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jun 2021
Eisai Inc. Announces the Appointment of Dr. Andree Amelsberg as Vice President, U.S. Medical Affairs, Oncology Business Group
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Dec 2020
Neuroglee Therapeutics to Attack Alzheimer's Disease Through Personalized AI-Powered Digital Therapeutics
Devices Neurology Venture Capital
 HSMN NewsFeed - 3 Feb 2020
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Aug 2019
Priya Chaturvedi, Ph.D., Appointed Vice President of Global Clinical Quality Assurance at Eisai Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Aug 2019
Bracco Diagnostics Inc. Receives U.S. FDA Approval for VARIBAR(R) THIN LIQUID (barium sulfate) for oral suspension
Biopharmaceuticals Radiology Gastroenterology FDA
 HSMN NewsFeed - 4 Jun 2019
Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2019
Calidi Biotherapeutics Announces The Appointment Of Seasoned Biotech Executive Dr. Ashok Srivastava To Their Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Mar 2019
Inovio Appoints Global Commercial Leader to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Mar 2019
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Dec 2018
BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 2 Nov 2018
BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jul 2018
BioArctic Announces Positive Topline Results of BAN2401 Phase 2b at 18 Months in Early Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Feb 2018
Arena Pharmaceuticals Announces Changes to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2018
Bracco Diagnostics Inc. receives U.S. Food and Drug Administration (FDA) approval for use of MultiHance(R) (gadobenate dimeglumine) injection in magnetic resonance imaging of the central nervous system in pediatric patients younger than two years of age
Biopharmaceuticals Devices Diagnostics Radiology FDA
 HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2017
Bracco Diagnostics Inc. Receives U.S. FDA Approval for TAGITOL(TM) V (Barium Sulfate) Oral Suspension
Biopharmaceuticals Radiology FDA
 HSMN NewsFeed - 5 Sep 2017
Morphotek(R), Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab(R)
Biopharmaceuticals Diagnostics Oncology Licensing
 HSMN NewsFeed - 28 Jul 2017
Bracco Diagnostics Inc. Receives U.S. FDA Approval for VARIBAR(R) NECTAR (barium sulfate) Oral Suspension
Diagnostics Radiology Gastroenterology FDA
 HSMN NewsFeed - 14 Jun 2017
Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2017
Bayer Expands Oncology Organization with Two New Leadership Team Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Apr 2017
Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 Mar 2017
Bracco Diagnostics Inc. announces the launch of the PROTOCO2L TOUCH(R) Colon Insufflator for use in CT Colonography procedures
Devices Radiology Oncology Product Launch
 HSMN NewsFeed - 5 Jan 2017
Eisai Acquires All Global Development And Marketing Rights For Chronic Weight Management Treatment Lorcaserin HCI
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 17 Nov 2016
FDA Grants Fast Track Designation for Development of E2609, Eisai's BACE Inhibitor for Early Alzheimer's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 3 Nov 2016
Eisai Welcomes Positive NICE recommendation for Halaven(R) (eribulin) for Patients with Locally Advanced or Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Sep 2016
Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven(R) (eribulin) in the Treatment of Advanced Liposarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Aug 2016
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 11 Apr 2016
Beyhan Zaim appointed Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group at Eisai Inc.
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 6 Apr 2016
Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai Inc.
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 4 Apr 2016
First Approval by U.S. Food and Drug Administration for Contrast Enhanced Ultrasonography of the Liver Received by Bracco Diagnostics Inc. for LUMASON(R) (sulfur hexafluoride lipid-type A microspheres) for Injectable Suspension, for Intravenous Use
Biopharmaceuticals Radiology FDA
 HSMN NewsFeed - 3 Mar 2016
Huya Bioscience International Expands Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Jan 2016
FDA Approves Eisai's Halaven(R) (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Dec 2015
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Apr 2015
Eiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Apr 2015
ImmunoGen, Inc. Appoints Anna Berkenblit, MD, MMSc Vice President and Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Feb 2015
Topline Results of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint of Overall Survival in Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2015
Pivotal Phase 3 Trial of Investigational Agent Lenvatinib in Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Oct 2014
FDA Approves AKYNZEO(R) (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2014
Eisai Sells U.S. Rights to Zonegran(R) (zonisamide) Capsules to Concordia Pharmaceuticals Inc.
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 23 Jun 2014
Barry Lederman Appointed Vice President and Chief Financial Officer of Eisai Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2014
Eisai Assigns Its Worldwide Exclusive License for DACOGEN(R) to Otsuka
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Jan 2014
Eisai Announces U.S. Availability of FYCOMPA(TM) (perampanel) CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 4 Dec 2013
TherapeuticsMD Appoints Joel S. Krasnow, M.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2013
Eisai Announces Availability of ACIPHEX(R) Sprinkle(TM) (Rabeprazole Sodium) for Treatment of GERD in Children Ages 1 to 11
Biopharmaceuticals Gastroenterology Product Launch
 HSMN NewsFeed - 30 Sep 2013
Alkermes Expands Senior Management Team
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 5 Sep 2013
Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Aug 2013
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jun 2013
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 7 Jun 2013
Eisai Announces Availability of BELVIQ(R) (lorcaserin HCl) CIV Tablets for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese
Biopharmaceuticals
 HSMN NewsFeed - 21 Feb 2013
Valeant Pharmaceuticals Acquires U.S. Rights to Targretin(R) from Eisai Inc.
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 17 Dec 2012
Eisai Inc. Divests U.S. Rights for GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant) to Arbor Pharmaceuticals
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 20 Nov 2012
Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
Biopharmaceuticals Personalized Medicine Oncology
 HSMN NewsFeed - 11 Oct 2012
Zyngenia, Inc. Expands Its Board of Directors with Leading Life Sciences Business Executives Christian Itin and Jason Rhodes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2012
Merz, Inc. Announces Cynthia Schwalm as Vice President, Neurology
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 22 Jun 2012
Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 May 2012
Eisai Gains Positive CHMP Opinion for Fycompa(R) (perampanel) First in a New Class of Treatment for Partial Onset Epilepsy
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 16 May 2012
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer
Biopharmaceuticals Personalized Medicine Personnel
 HSMN NewsFeed - 30 Apr 2012
Eisai Inc. Announces Appointment Of Senior Vice President And General Counsel, Allen Waxman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Mar 2012
Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Jan 2012
Interwest Partners Expands Medical Devices Team
Devices Venture Capital Personnel
 HSMN NewsFeed - 1 Nov 2011
H3 Biomedicine Names Markus Warmuth Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Sep 2011
SuperGen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol and New Website
Biopharmaceuticals
 HSMN NewsFeed - 25 Aug 2011
Celsion Announces the Appointment of Gary Renshaw, D.O., as Executive Medical Director
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 29 Jul 2011
U.S. FDA Provides Response to Perampanel New Drug Application
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 21 Jun 2011
TESARO Announces $101 Million Series B Financing for Advancement and Expansion of Oncology Product Portfolio
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 24 May 2011
Cerecor, Incorporated Initiates Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 May 2011
Optimer Pharmaceuticals Expands Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Apr 2011
FDA Issues Complete Response Letter for Aricept(R) Patch (donepezil transdermal system)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Mar 2011
TESARO Enters into Exclusive License Agreement with Amgen to Acquire Rights to Anaplastic Lymphoma Kinase (ALK) Program
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 Mar 2011
Eisai Realigns Its U.S. Operations
Biopharmaceuticals
 HSMN NewsFeed - 27 Jan 2011
H3 Biomedicine Launches to Discover and Develop Next Generation Cancer Treatments
Biopharmaceuticals Personalized Medicine Oncology
 HSMN NewsFeed - 25 Jan 2011
Eisai to Submit Marketing Authorization Applications in the U.S. and EU for Perampanel as Adjunctive Therapy for Partial Onset Seizures in Patients with Epilepsy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Jan 2011
Phase III Study for Eritoran Does Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 17 Nov 2010
Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2010
FDA Approves Eisai’s Halaven(TM) (Eribulin Mesylate) Injection for Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jul 2010
Eisai Inc. and Pfizer Inc Announce U.S. FDA Approval for New Higher-Dose Aricept(R) (donepezil HCl) 23 mg Tablet for the Treatment of Moderate-to-Severe Alzheimer's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 1 Jul 2010
Eisai to Market Arena Pharmaceuticals' Lorcaserin for Obesity and Weight Management in U.S. Following FDA Approval
Biopharmaceuticals
 HSMN NewsFeed - 1 Jul 2010
Eisai Inc. Enters Marketing and Supply Agreement with Arena Pharmaceuticals for Lorcaserin
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2010
Eisai Announces Results of Phase III Study of Dacogen(R) (Decitabine) for Injection in Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2010
Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 May 2010
Tesaro, Inc. Secures $60 Million in Start-up Funding
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 31 Mar 2010
Eisai Submits Marketing Authorisation Application for Approval of Eribulin Mesylate in Europe, Based on Significant Overall Survival in Late Stage Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Oct 2009
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
Biopharmacetuicals Onocology
 HSMN NewsFeed - 28 Oct 2009
Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Jul 2009
Abraxis BioScience Names Mary Lynne Hedley, Ph.D., Executive Vice President of Operations and Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jul 2009
Abraxis BioScience Appoints Rick Rodgers Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2009
Eisai and Pfizer Decide not to Appeal NICE Decision and Call for an Expedited Review of Guidance for Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 Jul 2009
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2009
Marty J. Duvall Joins Abraxis BioScience as Senior Vice President, Global Marketing and International Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2009
Lannett Company Receives FDA Approval for Pilocarpine HCI Tablets 7.5 mg Strength
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 30 Apr 2009
Abraxis BioScience Names Lonnie Moulder President and Chief Executive Officer; Soon-Shiong Remains Executive Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Apr 2009
TransMolecular Appoints Robert Radie President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Mar 2009
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Mar 2009
Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil
Biopharmaceuticals Drug Delivery Neurology Licensing
 HSMN NewsFeed - 9 Mar 2009
DiaMedica Appoints Stephen J. Waters as Interim Chief Scientific Officer
Biopharmaceuticals Endocrinology Personnel
 HSMN NewsFeed - 19 Feb 2009
Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 14 Dec 2008
FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Nov 2008
Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2008
Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All Claims
Biopharmaceuticals Litigation
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2008
Eisai Receives Action Letter on Fospropofol Disodium Injection for Sedation in Diagnostic or Therapeutic Procedures
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jul 2008
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jul 2008
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2008
Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 May 2008
Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Apr 2008
Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Apr 2008
European Regulatory Agency Grants Orphan Status to Morphotek(R)'s Farletuzumab and MORAb-009
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Apr 2008
Status of the E2007 (perampanel) Development Program - Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications
Biopharmaceuticals
 HSMN NewsFeed - 28 Mar 2008
Teva Provides Update on Generic Aricept(R) Litigation
Biopharmaceuticals Generics Litigation Neurology
 HSMN NewsFeed - 6 Mar 2008
Morphotek(R) Signs Exclusive Licensing Agreement for Anti-Cancer Antibody
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Mar 2008
FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Feb 2008
Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jan 2008
Eisai Completes Acquisition of MGI PHARMA
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Jan 2008
Myriad Genetics, Inc. Expands Commercial and Clinical Infrastructure
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2008
Eisai and MGI PHARMA Announce Early Termination of HSR Waiting Period for Eisai's Acquisition of MGI PHARMA
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Jan 2008
Teva Announces Tentative Approval of Generic Aricept(R) Tablets
Biopharmaceuticals Generics FDA Neurology
 HSMN NewsFeed - 27 Dec 2007
U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 10 Dec 2007
Eisai to Acquire MGI PHARMA for $41 Per Share in an All Cash Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Oct 2007
Eisai Holds Dedication Ceremony to Commemorate New U.S. Corporate Headquarters in Woodcliff Lake, NJ
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2007
TransMolecular, Inc. Names Morphotek Executive Nicholas C. Nicolaides, Ph.D., Chairman of the Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Oct 2007
Amira Pharmaceuticals Announces Appointment of Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2007
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Sep 2007
Orexigen(TM) Announces Settlement Agreement with Eisai
Biopharmaceuticals Litigation
 HSMN NewsFeed - 5 Sep 2007
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Salix Pharmaceuticals Acquires Patent-Protected Metoclopramide-Zydis(R)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Salix Pharmaceuticals Announces Co-Promotion Agreement for Balsalazide
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Aug 2007
Prestwick Pharmaceuticals, Inc. Strengthens Management Team with Appointment of Robert S. Radie as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jul 2007
Multinational study confirms positive effects of treatment with ARICEPT in patients with severe Alzheimer's disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Jul 2007
Sepracor Inc. and Eisai Co. Ltd. Announce Partnership for Development and Commercialization of LUNESTA(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 12 Jul 2007
Mersana Therapeutics, Inc. Appoints Pharmaceutical Industry Veteran Nicholas G. Bacopoulos, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2007
ONTAK(R) (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2007
Solstice Neurosciences, Inc. Announces Commercialization Agreement
Biopharmaceuticals
 HSMN NewsFeed - 2 May 2007
FDA Approves FRAGMIN(R) as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Apr 2007
Eisai Announces Completion of Acquisition of Morphotek
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Mar 2007
Eisai To Acquire Morphotek
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Feb 2007
Teva Announces Approval of Rabeprazole Sodium Delayed-Release Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 20 Feb 2007
Tapestry Pharmaceuticals Appoints Sandra L. Silberman, M.D., Ph.D. As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Nov 2006
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 8 Nov 2006
Solstice Neurosciences Raises $85 Million in Private Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Oct 2006
Ligand Completes Sale of Oncology Product Lines
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 25 Oct 2006
Eisai Announces Completion of Acquisition of Four Oncology-Related Products from Ligand
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 13 Oct 2006
U.S. Food and Drug Administration Approves ARICEPT(R) for Treatment of Severe Alzheimer's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 8 Oct 2006
Eisai Receives Summary Judgment Motion Decisions in U.S. Legal Action Over Aciphex(R) ANDA Filings
Biopharmaceuticals Litigation
 HSMN NewsFeed - 12 Jul 2006
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Jul 2006
Eisai Inc. Announces Appointment of Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 May 2006
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 May 2006
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
Biopharmaceuticals Neurology FDA
Return to NewsFeed  

 Additional items found! 73

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 73 additional stories matching:
Eisai
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.